Clinical Breakthrough: PleoPharma dosed the first patient in a pivotal Phase 3 trial of PP-01 (CAN-004) aimed at easing cannabis withdrawal symptoms in adults with cannabis use disorder, with FDA Fast Track status. Supreme Court Gun Rights: The U.S. Supreme Court unanimously ruled in United States v. Hemani that the federal government can’t automatically strip Second Amendment rights from marijuana users without showing they’re dangerous, reshaping how gun laws may apply to legal cannabis consumers. Regulatory Pressure on Hemp/CBD: Nebraska proposed rules that would treat food and beverages as adulterated/illegal if they contain any amount of THC and derivatives, drawing heavy opposition from the hemp and CBD industry. DEA Rescheduling Process: The DEA selected participants for a marijuana rescheduling hearing but invited only opponents, excluding reform supporters. Market Reality Check: Oklahoma’s cannabis market is collapsing amid oversupply and price drops, with officials pointing to diversion concerns. Product Access Update: Missouri’s new law will move intoxicating hemp products (THC-infused edibles/seltzers) out of retail and into state-licensed marijuana dispensaries starting Nov. 12. Local Care Expansion: Franklin Hospital launched a Comprehensive Addiction Medicine outpatient program to expand coordinated treatment for substance use disorders.